FDA 483 - Baxalta US Incorporated

An FDA inspection of Baxalta US Inc. in Los Angeles, CA, a blood fractionation manufacturing facility, identified two observations related to studies that did not meet predefined acceptance criteria. Specifically, environmental monitoring performance qualification studies and a study of washers were found to have failed their acceptance criteria without being repeated. This indicates potential issues with quality control and validation processes at the facility.